T cells are increasingly recognized as a critical element of the body’s protective immune response to a cancer. While traditional immunotherapy discovery methods have largely used predictive algorithms to find target antigens, we have been able to successfully leverage ATLASTM, our proprietary, high-throughput technology platform, to identify target antigens of T cells based on actual human immune responses.

We are focused on using ATLAS’s superiority (1) in neoantigen identification to develop neoantigen cancer vaccines. Neoantigens are personalized tumor mutations that are seen as ‘foreign’ by an individual’s immune system (2). Data published in recent years have indicated that an individual’s response to neoantigens drives checkpoint inhibitor efficacy (3) and that it is possible to vaccinate an individual against their own neoantigens (4).

GEN-009 is our most advanced candidate neoantigen vaccine for which we expect to initiate a Phase 1 clinical trial in the first half of 2018.  GEN-009 is an adjuvanted neoantigen peptide vaccine that is designed to direct a patient’s immune system to attack their tumor. GEN-009’s neoantigen peptides are identified by Genocea’s proprietary ATLAS platform, which recalls a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor. Following ATLAS neoantigen identification, Genocea will manufacture a personal vaccine for each patient.

Genocea is also seeking partners to use ATLAS to develop shared antigen cancer vaccines and vaccines against cancers of viral origin.

Genocea is headquartered in Cambridge, MA. We are a publicly traded company listed on NASDAQ under the ticker symbol GNCA.

References (1) https://www.genocea.com/assets/Kaufmann_AACR2017.pdf; (2) Yadav, Gubin, 2015; (3) Schumacher, Schreiber, 2015; (4) Ott, Sahin, et al 2017